SEC Form 4 · accession 0001609351-19-000010
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine A High
Officer — See Remarks · Director
Period of report
Jan 15, 2019
Accepted (ET)
Jan 17, 2019 · 9:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $42.73 | Jan 15, 2019 | A | 35,000 | A | — | Jan 15, 2029 | Common Stock | 35,000 | 35,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 15, 2019 | A | 10,000 | A | — | — | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F125% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years.
- F2Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic's Inc. common stock.
- F3The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date.
Remarks
President and Head of Research and Development